Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Gustave Roussy, the first cancer research and treatment center in France and Europe, maintains its position in the top 5 hospitals for oncology globally
For the fifth consecutive year, Newsweek magazine has ranked Gustave Roussy among the top five hospitals for oncology worldwide, highlighting its outstanding performance in both patient care and research.
Published on
For the fifth consecutive year, Newsweek magazine has ranked Gustave Roussy among the top five hospitals for oncology worldwide, highlighting its outstanding performance in both patient care and research.
First in France, first in Europe, and fourth globally. The World’s Best Specialized Hospital ranking, published by Newsweek magazine in collaboration with Statista, ranks the best hospitals worldwide each year, divided into 12 categories. For the 2025 edition, Gustave Roussy has been ranked fourth among the best hospitals for oncology globally for the second year in a row.
This ranking was established based on the results of an online survey sent to thousands of renowned health experts and on patient-reported quality indicators.
Continuity in excellence
“Being ranked for the second year in a row fourth best oncology hospital globally is a recognition of the outstanding commitment of Gustave Roussy’s healthcare providers, who are fully committed to curing cancer in the 21st century. It is Gustave Roussy’s continuity in excellence that is acknowledged here, in care as well as in research”, declares Prof. Fabrice Barlesi, Gustave Roussy’s General Director.
The Institute, which will celebrate in November the 150th birthday of its founder’s birth, has become over the last decades a major and innovative actor in global oncology. Its role in the emergence and development of precision medicine, immunotherapy, or radiotherapy is acknowledged today.
The commitment of all healthcare providers working every day at Gustave Roussy, 15 of whom are on the Clarivate / Web of Science list of the most highly cited researchers globally, is flawless. The expertise and work of the Institute's physician-researchers, some of whom lead international learned societies, are regularly recognized at international congresses. Gustave Roussy is also recognized for its ability to conduct early trials, thanks to its Department of Therapeutic Innovation and Early Trials (DITEP), one of the largest in Europe.
“This fourth place commits us once again to our patients, to keep offering them excellence in oncology, and to work relentlessly to find new therapeutic pathways. Gustave Roussy is driven by the desire to ensure that as many people as possible benefit from the advances developed within its walls, through the dissemination of these advances at international congresses or the industrialization of its discoveries. Major investments have been made in recent years in this direction, to build a true campus dedicated to oncology and precision medicine around the Institute and the Paris-Saclay Cancer Cluster. 2024 will mark the start of work on a brand new research center for Gustave Roussy, which, when inaugurated in 2028, will cover 32,800 square meters”, concludes Prof. Fabrice Barlesi.
► Consult the ranking and its methodology
Last news
-
Gustave Roussy at the ESMO 2026 Congress
The European Society for Medical Oncology (ESMO) is holding its annual congress from 23 to 27 October in Madrid, Spain. This major international event provides oncologists and researchers from around the world with an opportunity to present the latest findings from clinical studies aimed at improving cancer care and deepening our understanding of the disease. Once again, this year, physicians and researchers from Gustave Roussy have contributed to several dozen studies that will be presented during the five-day congress.
-
5 questions with Dr François-Xavier Danlos about therapeutic cancer vaccines
Therapeutic cancer vaccines are making significant progress in clinical development. The ESMO Congress, which begins on 23 October, will provide an opportunity to learn about new data on a therapeutic vaccine against melanoma. However, there are major differences between vaccines traditionally used to prevent disease and therapeutic cancer vaccines. Dr François-Xavier Danlos, a medical oncologist in Gustave Roussy’s Drug Development Department and a specialist in immunotherapy development, explains.
-
ADCs: Two Landmark Publications in Cancer Cell and Nature Medicine Showcase Gustave Roussy's Expertise
In less than two months, researchers and clinicians from Gustave Roussy have contributed to two major publications on Antibody-Drug Conjugates (ADCs) in Cancer Cell and Nature Medicine. Together, these papers provide both a comprehensive overview of current knowledge and a strategic vision to accelerate the development of the next generation of these innovative therapies.
-
Drug shortages: Gustave Roussy becomes the only Cancer Centre in France authorised to produce Special Hospital Preparations
The Clinical Pharmacy Department at Gustave Roussy has been authorised by the French Ministry of Health to manufacture Special Hospital Preparations (SHPs). Granted for a period of seven years, this accreditation enables the Institute’s hospital pharmacy to produce certain medicines in coordination with the French National Agency for the Safety of Medicines and Health Products (ANSM) and the Ministry of Health. Gustave Roussy is the only French Comprehensive Cancer Centre (CLCC) authorised to manufacture Special Hospital Preparations, alongside ten university hospitals.
